<?xml version='1.0' encoding='UTF-8'?>
<rss xmlns:arxiv="http://arxiv.org/schemas/atom" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" version="2.0">
  <channel>
    <title>q-bio.OT updates on arXiv.org</title>
    <link>http://rss.arxiv.org/rss/q-bio.OT</link>
    <description>q-bio.OT updates on the arXiv.org e-print archive.</description>
    <atom:link href="http://rss.arxiv.org/rss/q-bio.OT" rel="self" type="application/rss+xml"/>
    <docs>http://www.rssboard.org/rss-specification</docs>
    <language>en-us</language>
    <lastBuildDate>Tue, 18 Feb 2025 05:00:08 +0000</lastBuildDate>
    <managingEditor>rss-help@arxiv.org</managingEditor>
    <pubDate>Tue, 18 Feb 2025 00:00:00 -0500</pubDate>
    <skipDays>
      <day>Sunday</day>
      <day>Saturday</day>
    </skipDays>
    <item>
      <title>Conditional Success of Adaptive Therapy: The Role of Treatment-Holiday Thresholds Revealed by Mathematical Modeling</title>
      <link>https://arxiv.org/abs/2502.09392</link>
      <description>arXiv:2502.09392v2 Announce Type: replace 
Abstract: Adaptive therapy (AT) improves cancer treatment by controlling the competition between sensitive and resistant cells through treatment holidays. This study highlights the critical role of treatment-holiday thresholds in AT for tumors composed of drug-sensitive and resistant cells. Using a Lotka-Volterra model, the research compares AT with maximum tolerated dose therapy and intermittent therapy, showing that AT's success largely depends on the threshold at which treatment is paused and resumed, as well as on the competition between sensitive and resistant cells. Three scenarios of comparison between AT and other therapies are identified: uniform-decline, conditional-improve, and uniform-improve, illustrating that optimizing the treatment-holiday threshold is crucial for AT effectiveness. Tumor composition, including initial tumor burden and the proportion of resistant cells, influences outcomes. Adjusting threshold values enables AT to suppress resistant subclones, preserving sensitive cells, ultimately improving progression-free survival. These findings emphasize the importance of personalized treatment strategies potentially enhancing long-term therapeutic outcomes.</description>
      <guid isPermaLink="false">oai:arXiv.org:2502.09392v2</guid>
      <category>q-bio.OT</category>
      <pubDate>Tue, 18 Feb 2025 00:00:00 -0500</pubDate>
      <arxiv:announce_type>replace</arxiv:announce_type>
      <dc:rights>http://arxiv.org/licenses/nonexclusive-distrib/1.0/</dc:rights>
      <dc:creator>Lanfei Sun, Haifeng Zhang, Kai Kang, Xiaoxin Wang, Leyi Zhang, Yanan Cai, Changjing Zhuge, Lei Zhang</dc:creator>
    </item>
  </channel>
</rss>
